KRAS and non-small cell lung carcinoma: We recently showed that SOS2 is specifically required for PI3K-dependent protection from anoikis in KRAS-mutated NSCLC cells (Sheffels et al., 2019) and SOS2 deletion synergizes with MEK inhibition to kill KRAS mutated cells only under 3D culture conditions (Sheffels et al., 2018).